naproxen + esomeprazole
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Juvenile Idiopathic Arthritis
Conditions
Juvenile Idiopathic Arthritis
Trial Timeline
May 1, 2011 → Jun 1, 2011
NCT ID
NCT01358383About naproxen + esomeprazole
naproxen + esomeprazole is a phase 1 stage product being developed by AstraZeneca for Juvenile Idiopathic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01358383. Target conditions include Juvenile Idiopathic Arthritis.
What happened to similar drugs?
0 of 20 similar drugs in Juvenile Idiopathic Arthritis were approved
Approved (0) Terminated (2) Active (18)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01358383 | Phase 1 | Completed |
Competing Products
20 competing products in Juvenile Idiopathic Arthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PLX-200 + Placebo | Polaryx Therapeutics | Phase 3 | 37 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 40 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 40 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 40 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 40 |
| Adalimumab | Eisai | Phase 3 | 40 |
| Abatacept | Ono Pharmaceutical | Phase 3 | 40 |
| Ixekizumab + Adalimumab | Eli Lilly | Phase 3 | 44 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 40 |
| Baricitinib | Eli Lilly | Phase 3 | 47 |
| Baricitinib + Tocilizumab | Eli Lilly | Phase 3 | 47 |
| adalimumab + Methotrexate | AbbVie | Pre-clinical | 26 |
| Upadacitinib | AbbVie | Phase 1 | 33 |
| Upadacitinib + Tocilizumab | AbbVie | Phase 3 | 47 |
| Adalimumab + Risankizumab | AbbVie | Phase 3 | 47 |
| Adalimumab | AbbVie | Phase 3 | 40 |
| Alendronate (Fosamax) | Merck | Pre-clinical | 26 |
| canakinumab | Novartis | Phase 3 | 40 |
| Secukinumab | Novartis | Phase 1 | 36 |
| ACZ885 150 mg (Canakinumab) | Novartis | Phase 3 | 40 |